VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood tests for a broad range of cancer types and other conditions, today announced the grant of US Patent Number 9,128,086 entitled "Detection of Histone Modification in Cell-Free Nucleosomes". This patent is already issued in Europe to the Company under the number EP1668368B1.
The key new U.S. patent, issued yesterday and expiring in mid-2029, relates to the detection of epigenetic changes that affect chromosome structure in cancer, by means of a simple test using a single drop of blood. VolitionRx's Nucleosomics® platform detects changes to histone proteins contained in fragments of chromosomes, called nucleosomes, that circulate in the blood of cancer patients.
Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, remarked, "VolitionRx is building a world-wide portfolio of intellectual property to protect its Nucleosomics® technology for detecting cancer and other diseases in blood samples and biological fluids. The grant of U.S. Patent 9,128,086 provides protection to key technology that underpins our NuQ® tests as we continue towards our goals of commercialization and helping as many patients as possible."
Cameron Reynolds, Chief Executive Officer of VolitionRx, added, "Our first granted patent in the U.S. is a key milestone for VolitionRx in our path to commercialization of our proprietary Nucleosomics® platform. Since the Company's inception, our mission has been to develop accurate and cost-effective detection tools for early-stage cancer and other conditions. We have made great progress through exhaustive work in R&D and clinical trials. The grant of this broad-reaching, wholly-owned and royalty-free patent is a critical step in protecting VolitionRx's intellectual property and consequently shareholder value."
SOURCE VolitionRx Ltd